Browse Technologies
Keyword Search
COVID-19
Harvard faculty across the university are engaged in urgent research efforts to stem the tide of the COVID-19 pandemic and ensure preparedness for future outbreaks. We invite you to browse the projects below and consider areas within your expertise where additional academic-industry collaboration could accelerate these efforts to make a difference and save lives.
Search Results
Displaying: 1 - 6 of 6 Results
Rapid point-of-care COVID-19 detection assay by RT-LAMP
The current SARS-CoV-2 pandemic has created an urgent need for rapid point-of-care diagnostic tools. Many of these tests are being developed and are achieving FDA approval. In the face of a sweeping pandemic, assays should require no specialized…
DBD
- Grant Zimmermann
Investigators
- Constance Cepko
Extracellular vesicles for COVID-19 vaccine development
The laboratory of Quan Lu at the Harvard T.H. Chan School of Public Health has developed an innovative vaccine platform that features a novel antigen display technology that has been shown to elicit broadly neutralizing antibody responses from…
DBD
- Grant Zimmermann
Investigators
- Quan Lu
Utilizing the herpes simplex virus-based vaccine vectors to develop a COVID-19 vaccine
Researchers in the lab of David Knipe have constructed the HSV-1 based vaccine vector HSV-1 d106S. The vector can express viral, bacterial, or cancer gene products and has been used to induce protective immunity in humanized mice against HIV and…
DBD
- Vivian Berlin
Investigators
- David Knipe
Machine learning to accelerate diagnostics and therapeutics for COVID-19
The COVID-19 pandemic demands a rapid response of science, diagnostics, and therapeutics. Debora Marks’ lab at Harvard Medical School aims to accelerate those efforts using predictive models of the SARS-CoV2-19 sequences and 3D structures. The lab’s…
DBD
- Irit Ben-Chelouche
Investigators
- Debora Marks
Novel adjuvants to enhance adaptive immune response of vaccines
Researchers in the lab of Ulrich von Andrian have discovered a novel adjuvanting behavior of a clinically approved and well-tolerated class of medicines known as bisphosphonates. The team is hoping to collaborate with manufacturers of COVID-19…
DBD
- Irit Ben-Chelouche
Investigators
- Ulrich von Andrian
Self-adjuvanting mRNA platform technology
Researchers in the lab of Prof. George Church at Harvard Medical School have developed a vaccine platform technology that can be applied to fields such as infectious diseases and oncology therapeutics. The team is looking to further demonstrate…
DBD
- Grant Zimmermann
Investigators
- George Church